Corcept Therapeutics Incorporated (0I3Q.L)
USD 62.6
(-3.22%)
USD 62.6
(-3.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 108.32 Million USD | -2.65% |
| 2022 | 112.63 Million USD | -9.51% |
| 2021 | 124.47 Million USD | -2.91% |
| 2020 | 130.43 Million USD | 14.87% |
| 2019 | 113.77 Million USD | 24.71% |
| 2018 | 89.73 Million USD | 69.32% |
| 2017 | 52.96 Million USD | 414.85% |
| 2016 | 10.26 Million USD | 412.23% |
| 2015 | -3.28 Million USD | 88.03% |
| 2014 | -27.47 Million USD | 33.66% |
| 2013 | -41.42 Million USD | -14.28% |
| 2012 | -36.24 Million USD | -12.2% |
| 2011 | -32.35 Million USD | -17.87% |
| 2010 | -25.96 Million USD | -35.52% |
| 2009 | -20.25 Million USD | -10.14% |
| 2008 | -19.68 Million USD | -50.3% |
| 2007 | -12.24 Million USD | 52.2% |
| 2006 | -25.58 Million USD | -25.27% |
| 2005 | -20.08 Million USD | -42.01% |
| 2004 | -15.46 Million USD | -44.07% |
| 2003 | -9.97 Million USD | 46.94% |
| 2002 | -18.79 Million USD | -134.76% |
| 2001 | -8 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 29.62 Million USD | -8.13% |
| 2024 Q2 | 35.84 Million USD | 20.16% |
| 2024 Q3 | 47.09 Million USD | 30.92% |
| 2023 Q3 | 31.34 Million USD | 3.09% |
| 2023 Q1 | 14.85 Million USD | -33.98% |
| 2023 FY | - USD | -2.65% |
| 2023 Q2 | 30.4 Million USD | 104.71% |
| 2023 Q4 | 32.29 Million USD | 3.04% |
| 2022 Q3 | 32.68 Million USD | 3.99% |
| 2022 Q1 | 27.57 Million USD | -24.8% |
| 2022 Q4 | 22.49 Million USD | -31.17% |
| 2022 FY | - USD | -9.51% |
| 2022 Q2 | 31.43 Million USD | 14.0% |
| 2021 Q4 | 36.66 Million USD | -0.92% |
| 2021 Q3 | 37 Million USD | 13.16% |
| 2021 Q2 | 32.69 Million USD | 60.44% |
| 2021 FY | - USD | -2.91% |
| 2021 Q1 | 20.38 Million USD | -33.2% |
| 2020 FY | - USD | 14.87% |
| 2020 Q3 | 25.28 Million USD | -29.32% |
| 2020 Q2 | 35.77 Million USD | -5.14% |
| 2020 Q1 | 37.71 Million USD | 7.7% |
| 2020 Q4 | 30.51 Million USD | 20.67% |
| 2019 FY | - USD | 24.71% |
| 2019 Q2 | 24.63 Million USD | 26.55% |
| 2019 Q1 | 19.46 Million USD | -21.82% |
| 2019 Q4 | 35.01 Million USD | 4.28% |
| 2019 Q3 | 33.57 Million USD | 36.32% |
| 2018 Q4 | 24.89 Million USD | 8.13% |
| 2018 FY | - USD | 69.32% |
| 2018 Q2 | 20.69 Million USD | -1.45% |
| 2018 Q3 | 23.02 Million USD | 11.29% |
| 2018 Q1 | 20.99 Million USD | -3.24% |
| 2017 Q4 | 21.69 Million USD | 59.27% |
| 2017 Q2 | 12.79 Million USD | 169.94% |
| 2017 Q3 | 13.62 Million USD | 6.47% |
| 2017 FY | - USD | 414.85% |
| 2017 Q1 | 4.74 Million USD | -5.62% |
| 2016 Q1 | 619 Thousand USD | -63.13% |
| 2016 Q2 | 1.5 Million USD | 143.62% |
| 2016 Q3 | 3.09 Million USD | 105.11% |
| 2016 Q4 | 5.02 Million USD | 62.37% |
| 2016 FY | - USD | 412.23% |
| 2015 Q3 | 132 Thousand USD | 111.9% |
| 2015 Q4 | 1.67 Million USD | 1171.97% |
| 2015 Q2 | -1.1 Million USD | 72.21% |
| 2015 FY | - USD | 88.03% |
| 2015 Q1 | -3.99 Million USD | -31.25% |
| 2014 Q2 | -6.54 Million USD | 49.0% |
| 2014 Q3 | -5.06 Million USD | 22.62% |
| 2014 FY | - USD | 33.66% |
| 2014 Q4 | -3.04 Million USD | 39.97% |
| 2014 Q1 | -12.83 Million USD | -28.19% |
| 2013 Q2 | -10.76 Million USD | 1.51% |
| 2013 FY | - USD | -14.28% |
| 2013 Q4 | -10 Million USD | -2.97% |
| 2013 Q3 | -9.72 Million USD | 9.7% |
| 2013 Q1 | -10.92 Million USD | -9.55% |
| 2012 Q3 | -7.65 Million USD | -0.98% |
| 2012 Q2 | -7.58 Million USD | 31.2% |
| 2012 FY | - USD | -12.2% |
| 2012 Q1 | -11.02 Million USD | -11.12% |
| 2012 Q4 | -9.97 Million USD | -30.3% |
| 2011 Q2 | -8.85 Million USD | -24.87% |
| 2011 FY | - USD | -17.87% |
| 2011 Q1 | -7.09 Million USD | -0.37% |
| 2011 Q4 | -9.91 Million USD | -54.1% |
| 2011 Q3 | -6.43 Million USD | 27.33% |
| 2010 Q4 | -7.06 Million USD | 0.48% |
| 2010 FY | - USD | -35.52% |
| 2010 Q3 | -7.1 Million USD | 1.24% |
| 2010 Q2 | -7.19 Million USD | -18.84% |
| 2010 Q1 | -6.05 Million USD | -17.48% |
| 2009 Q4 | -5.15 Million USD | -10.4% |
| 2009 FY | - USD | -10.14% |
| 2009 Q3 | -4.66 Million USD | 4.37% |
| 2009 Q2 | -4.87 Million USD | 11.77% |
| 2009 Q1 | -5.52 Million USD | 2.38% |
| 2008 Q3 | -3.94 Million USD | 15.63% |
| 2008 Q2 | -4.67 Million USD | -14.72% |
| 2008 Q1 | -4.07 Million USD | 7.51% |
| 2008 FY | - USD | -50.3% |
| 2008 Q4 | -5.66 Million USD | -43.57% |
| 2007 Q3 | -3.61 Million USD | -129.54% |
| 2007 Q4 | -4.4 Million USD | -21.98% |
| 2007 FY | - USD | 52.2% |
| 2007 Q1 | -2.62 Million USD | 34.3% |
| 2007 Q2 | -1.57 Million USD | 39.97% |
| 2006 Q3 | -6.53 Million USD | 18.85% |
| 2006 Q2 | -8.05 Million USD | -15.55% |
| 2006 Q4 | -3.99 Million USD | 38.96% |
| 2006 Q1 | -6.97 Million USD | -31.96% |
| 2006 FY | - USD | -25.27% |
| 2005 Q3 | -5.25 Million USD | -20.03% |
| 2005 Q1 | -5.47 Million USD | -5.96% |
| 2005 FY | - USD | -42.01% |
| 2005 Q4 | -5.28 Million USD | -0.53% |
| 2005 Q2 | -4.37 Million USD | 19.99% |
| 2004 Q4 | -5.16 Million USD | -27.2% |
| 2004 FY | - USD | -44.07% |
| 2004 Q2 | -3.15 Million USD | -53.49% |
| 2004 Q3 | -4.06 Million USD | -28.73% |
| 2004 Q1 | -2.05 Million USD | -0.76% |
| 2003 Q2 | -2.91 Million USD | -1.99% |
| 2003 Q4 | -2.03 Million USD | 5.42% |
| 2003 Q3 | -2.15 Million USD | 26.06% |
| 2003 FY | - USD | 46.94% |
| 2003 Q1 | -2.85 Million USD | 0.0% |
| 2002 FY | - USD | -134.76% |
| 2001 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| uniQure N.V. | -253.1 Million USD | 142.799% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 314.198% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 223.116% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 93.541% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 131.356% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 147.485% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 217.642% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 294.282% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 140.724% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 148.146% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 65.089% |
| bluebird bio, Inc. | -167.16 Million USD | 164.802% |
| Blueprint Medicines Corporation | -474.61 Million USD | 122.824% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 192.073% |
| Imunon, Inc. | -20.78 Million USD | 621.233% |
| Adicet Bio, Inc. | -136.53 Million USD | 179.338% |
| Dynavax Technologies Corporation | 9.66 Million USD | -1020.67% |
| Editas Medicine, Inc. | -163.11 Million USD | 166.409% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 121.438% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 172.164% |
| Exelixis, Inc. | 196.6 Million USD | 44.902% |
| FibroGen, Inc. | -261.4 Million USD | 141.439% |
| Geron Corporation | -174.78 Million USD | 161.977% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 76.032% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 204.366% |
| Illumina, Inc. | -608 Million USD | 117.816% |
| Incyte Corporation | 919.42 Million USD | 88.218% |
| Insmed Incorporated | -654.73 Million USD | 116.545% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 121.395% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 147.095% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 124.125% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 96.673% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 400.216% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 90.694% |
| Evolus, Inc. | -41.81 Million USD | 359.086% |
| Myriad Genetics, Inc. | -67.8 Million USD | 259.77% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 73.967% |
| OPKO Health, Inc. | -65.51 Million USD | 265.34% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 124.664% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -10.24% |
| Verastem, Inc. | -83.16 Million USD | 230.25% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 100.96% |
| Waters Corporation | 1.02 Billion USD | 89.403% |
| Zoetis Inc. | 3.68 Billion USD | 97.06% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 97.648% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 98.997% |
| Biogen Inc. | 2.37 Billion USD | 95.443% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 223.902% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 97.673% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 343.771% |
| Homology Medicines, Inc. | -47.75 Million USD | 326.828% |
| Nektar Therapeutics | -243.1 Million USD | 144.558% |
| TG Therapeutics, Inc. | 26.1 Million USD | -315.034% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 207.436% |
| Perrigo Company plc | 646.2 Million USD | 83.237% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 390.545% |